肿瘤药学
腫瘤藥學
종류약학
ANTI-TUMOR PHARMACY
2015年
1期
42-45
,共4页
茅力平%沈飞%孙雅君%刘振宗%沈萍
茅力平%瀋飛%孫雅君%劉振宗%瀋萍
모력평%침비%손아군%류진종%침평
结直肠癌%糖类抗原199%癌胚抗原%预后
結直腸癌%糖類抗原199%癌胚抗原%預後
결직장암%당류항원199%암배항원%예후
Colorectalcancer%CA199%CEA%Prognosis
目的:探讨联合检测结直肠癌术前血清CA199、CEA对预后评估的作用。方法采集126例结直肠癌术前血清,通过免疫分析法检测血清中CA199和CEA含量,并根据检验结果划分为CA199(-)/CEA (-)、CA199(-)/CEA(+)、CA199(+)/CEA(-)及CA199(+)/CEA(+)四个组,比较其临床分期和生存期。结果 CA199(+)与肿瘤浸润程度、淋巴结转移及分期有一定相关性,且与CA199(-)比较,差异有统计学意义(P<0.05)。CA199(+)/CEA(+)患者生存期远远低于其它三组;CA199(+)/CEA(-)组患者生存期要低于CA199(-)/CEA(+),差异有统计学意义(P<0.05)。结论结直肠癌术前血清CA199阳性者比CEA阳性者呈更短的生存期,CA199(+)/CEA(+)组预后更差,临床应重视CA199阳性患者的预后。
目的:探討聯閤檢測結直腸癌術前血清CA199、CEA對預後評估的作用。方法採集126例結直腸癌術前血清,通過免疫分析法檢測血清中CA199和CEA含量,併根據檢驗結果劃分為CA199(-)/CEA (-)、CA199(-)/CEA(+)、CA199(+)/CEA(-)及CA199(+)/CEA(+)四箇組,比較其臨床分期和生存期。結果 CA199(+)與腫瘤浸潤程度、淋巴結轉移及分期有一定相關性,且與CA199(-)比較,差異有統計學意義(P<0.05)。CA199(+)/CEA(+)患者生存期遠遠低于其它三組;CA199(+)/CEA(-)組患者生存期要低于CA199(-)/CEA(+),差異有統計學意義(P<0.05)。結論結直腸癌術前血清CA199暘性者比CEA暘性者呈更短的生存期,CA199(+)/CEA(+)組預後更差,臨床應重視CA199暘性患者的預後。
목적:탐토연합검측결직장암술전혈청CA199、CEA대예후평고적작용。방법채집126례결직장암술전혈청,통과면역분석법검측혈청중CA199화CEA함량,병근거검험결과화분위CA199(-)/CEA (-)、CA199(-)/CEA(+)、CA199(+)/CEA(-)급CA199(+)/CEA(+)사개조,비교기림상분기화생존기。결과 CA199(+)여종류침윤정도、림파결전이급분기유일정상관성,차여CA199(-)비교,차이유통계학의의(P<0.05)。CA199(+)/CEA(+)환자생존기원원저우기타삼조;CA199(+)/CEA(-)조환자생존기요저우CA199(-)/CEA(+),차이유통계학의의(P<0.05)。결론결직장암술전혈청CA199양성자비CEA양성자정경단적생존기,CA199(+)/CEA(+)조예후경차,림상응중시CA199양성환자적예후。
ObjectiveToinvestigatethevalueoftheprognosisevaluationsofjointdetectionofserumCA199andCEA before operation for the prognosis evaluation of colorectal cancer patients.Methods Serums were collected from 126 patients with colorectal cancer before operation. Immunoassay was employed to determine their CA199 and CEA contents. Accord-ing to the results, the patients were classified into four groups:CA199(-)/CEA(-), CA199(-)/CEA(+), CA199(+)/CEA(-) and CA199(+)/CEA(+). Their clinical stages and survival time were compared. Results CA199(+) was related to tumor infiltrat-ing degree, lymph node metastasis and stage, and when compared with CA199(-), differences were statistically significant (P<0.05). The patients' survival time in CA199(+)/CEA(+) group was much shorter than in the other three groups. The patients' survival time in CA199(+)/CEA(-) group was shorter than in CA199(-)/CEA(+) group (P<0.05). Conclusion De-tection of serum before colorectal cancer operation, CA199 positive patients have shorter survival time than CEA positive patients, and CA199(+)/CEA(+) patients would have even poorer prognosis. It is important to pay attention to the prognosis of CA199 positive patients.